A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals’ Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in Japan

    NEXT STORY
    Medical Mask Market to Grow at 8.5% CAGR and Touch USD 2.15 Billion by 2027; Driven by Growing Investments in Product Manufacturing, says Fortune Business Insights™
    PREV STORY
    Allied Expands Pharmaceutical Pipeline By Filing US Provisional Patent for Psilocybin Based Therapeutics
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference

    OXFORD, United Kingdom and CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics ...

    author_avatar
    NASDAQ Market News

    FibroGen Reports Third Quarter 2019 Financial Results

    author_avatar
    NASDAQ Market News

    Streamline Health® Reports Fourth Quarter and Fiscal Year 2019 Financial Results

    author_avatar
    NASDAQ Market News